Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Sarcoma 18Osteosarcoma 7Neoplasm Metastasis 6Lymphoma, Non-Hodgkin 6Glioma 6Ependymoma 6Carcinosarcoma 6Rhabdomyosarcoma 5Neuroblastoma 5Medulloblastoma 5Liposarcoma 5Leiomyosarcoma 5Central Nervous System Neoplasms 5Neuroectodermal Tumors, Primitive, Peripheral 4Lymphoma, Follicular 4Histiocytosis, Langerhans-Cell 4Histiocytoma, Malignant Fibrous 4Gliosarcoma 4Glioblastoma 4Endometrial Neoplasms 4Wilms Tumor 3Sarcoma, Kaposi 3Rhabdoid Tumor 3Prostatic Neoplasms 3Oligodendroglioma 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hepatoblastoma 3

Interventions

Ifosfamide 3Doxorubicin 3Radiotherapy 2Imatinib Mesylate 2Filgrastim 2trebananib 1selurampanel 1selinexor 1saracatinib 1perifosine 1elacestrant 1Trabectedin 1Thalidomide 1Temozolomide 1Sunitinib 1RAD1901 1Postmortem Imaging 1Paclitaxel 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Injections 1High-Energy Shock Waves 1Fulvestrant 1Cyproheptadine 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Endometrial Stromal × Biopsy × Sarcoma × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡